Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Mufti

Showing results (11-20 of 202) with videos related to

Pageof 21
Sort By:
Bone Marrow Transplantation|May 1, 1995
Single dose of filgrastim (rhG-CSF) to predict mobilisation of haemopoietic progenitors in patients with haematological malignanciesA Mijovic, G J Mufti
BMJ (Clinical Research Ed.)|March 9, 1991
Warnings over cling filmA Pagliuca, G J Mufti
Haematologia|January 1, 1993
The pathophysiology and management of HIV-associated haematological abnormalitiesR S Kaczmarski, G J Mufti
The New England Journal of Medicine|October 21, 1993
Low-dose filgrastim therapy for chronic neutropeniaR S Kaczmarski, G J Mufti
Blut|December 1, 1986
Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemiaD M Layton, G J Mufti
Blood Reviews|September 1, 1991
The cytokine receptor superfamilyR S Kaczmarski, G J Mufti
Lancet (London, England)|July 8, 1998
Opiates for sickle-cell crisis?D M Layton, G J Mufti
British Medical Journal (Clinical Research Ed.)|July 25, 1987
The myelodysplastic syndromesD M Layton, G J Mufti
Clinics in Haematology|November 1, 1986
Myelodysplastic syndromes: natural history and features of prognostic importanceG J Mufti, D A Galton
Leukemia Research|November 1, 1994
The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromesW J Hirst, G J Mufti
Pageof 21

Showing results (11-20 of 202) with videos related to

Sort By:
Pageof 21
Bone Marrow Transplantation|May 1, 1995
Single dose of filgrastim (rhG-CSF) to predict mobilisation of haemopoietic progenitors in patients with haematological malignanciesA Mijovic, G J Mufti
BMJ (Clinical Research Ed.)|March 9, 1991
Warnings over cling filmA Pagliuca, G J Mufti
Haematologia|January 1, 1993
The pathophysiology and management of HIV-associated haematological abnormalitiesR S Kaczmarski, G J Mufti
The New England Journal of Medicine|October 21, 1993
Low-dose filgrastim therapy for chronic neutropeniaR S Kaczmarski, G J Mufti
Blut|December 1, 1986
Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemiaD M Layton, G J Mufti
Blood Reviews|September 1, 1991
The cytokine receptor superfamilyR S Kaczmarski, G J Mufti
Lancet (London, England)|July 8, 1998
Opiates for sickle-cell crisis?D M Layton, G J Mufti
British Medical Journal (Clinical Research Ed.)|July 25, 1987
The myelodysplastic syndromesD M Layton, G J Mufti
Clinics in Haematology|November 1, 1986
Myelodysplastic syndromes: natural history and features of prognostic importanceG J Mufti, D A Galton
Leukemia Research|November 1, 1994
The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromesW J Hirst, G J Mufti
Pageof 21